-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Management of Hemolytic Anemia Following Allogeneic Stem Cell Transplantation

Program: Education Program
Session: New Insights in Hemolytic Anemia
Saturday, December 5, 2015, 9:30 AM-11:00 AM
W331, Level 3 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
W331, Level 3 (Orange County Convention Center)

Andreas Holbro, MD

Division of Hematology, University Hospital Basel, Basel, Switzerland

Disclosures: Holbro: CSL Behring: Research Funding ; Novartis: Research Funding ; Teva: Consultancy ; Amgen: Consultancy . Off Label Use: Rituximab, Defibrotide, Vincristine, Eculizumab and pravastatin for the treatment of TA-TMA. Rituximab for the treatment of AIHA..

See more of: New Insights in Hemolytic Anemia
See more of: Education Program
Previous Presentation | Next Presentation >>